Hengrui Medicine drug application accepted, share buyback updated

Jiangsu Hengrui Medicine announced the acceptance by China's National Medical Products Administration of its marketing authorization application for Remimazolam Tosilate for injection. The drug's proposed indication is for sedation during mechanical ventilation in intensive care unit patients, with its advantages noted as rapid onset, short recovery time, and minimal impact on respiratory and cardiovascular systems. This development follows previous approvals for other indications. The cumulative R&D investment for this project reached CNY 18,400 million.

Concurrently, the company provided an update on its A-share buyback program. As of November 30, 2025, Jiangsu Hengrui Medicine has cumulatively repurchased 8.8987 million shares, representing 0.13% of its total share capital. The highest price paid was CNY 70.00/share, and the lowest was CNY 59.32/share, with a total expenditure of CNY 59,521.63 million (excluding transaction fees). The buyback, which aims to support employee stock ownership plans or equity incentives, is progressing within the previously announced timeframe and budget of CNY 100,000 million to CNY 200,000 million.